Screener / SEC EDGAR /CIK 0000886163 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq, OTC Health care · Pharmaceuticals

Ligand Pharmaceuticals Inc LGND

Compare with peers Embed
SEC comment letters, last 20 years

3 reviews of LGND's filings by SEC staff

UPLOAD and CORRESP
Reviews 3 latest letter Dec 23, 2020
Questions asked 8 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 4 UPLOAD
  2. 2. Questions in them 8 numbered comments
  3. 3. Company replies 4 CORRESP
  4. 4. Reviews closed 3 of 3 closing letter

Half the closed reviews took 54 days or less from the first letter to the closing letter.

Form 10-K for the Year Ended December 31, 2019

2020-12-23 to 2021-01-13 · 3 questions · 1 letter from the SEC, 1 from the company
Review closed 2021-01-13
AcquisitionsRisk factorsLegal and contingenciesDerivatives and hedgingResults discussion (MD&A)Income taxes
Annual Report on Form 10-K for the Year ended December 31, 2019 · General
SEC asked (1)
We note that Article IX, Section 7 of your Third Amended and Restated Bylaws identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any "derivative action." In future filings, please prominently describe the provision, including the relevant forum for litigation and any subject matter jurisdiction carve out, and whether this provision applies to actions
Rest of the question

arising under the Securities Act or Exchange Act. If so, please also state that there is uncertainty as to whether a court would enforce such provision and include risk factor disclosure of the risks to investors, such as the increased costs to bring a claim and that the provision may discourage claims or limit investors' ability to bring a claim in a judicial forum that they find favorable. Further, if the provision applies to Securities Act claims, please also state that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. In that regard, we note that Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.

LGND answered
In response to the Staff’s comment, the Company will add the following risk factor in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 (“2020 Form 10-K”), and similar Choice of Forum disclosure in the Description of Capital Stock exhibit to such Form 10-K, and other future filings where applicable:

“Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for
Rest of the answer

disputes with us or our directors, officers or employees.

Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the General Corporation Law of Delaware or our amended and restated certificate of incorporation or amended and restated bylaws, or (iv) any action asserting a claim governed by the internal affairs doctrine. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act provides for concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, and as such, the exclusive jurisdiction clauses set forth above would not apply to such suits. The choice of forum provisions in our amended and restated bylaws may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to these provisions, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies’ certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.”

Read in the reply
Management's Discussion and Analysis, page 40
SEC asked (2)
We note the significant increase in your research and development expenses from $28 million in 2018 to $56 million in 2019 as well as that these costs represented approximately 44% of your total operating costs in 2019.
Rest of the question

In this regard, please provide more detail regarding your research and development expenses for each period presented, including but not limited to by program as well as by the nature of the expenses. To the extent that you do not track expenses by program, please disclose as such. In addition, you disclose that research and development expenses increased year over year in 2019 due to the timing of internal development costs, the Vernalis acquisition, and the amortization of other economic rights during 2019. Please quantify the impact of each significant factor that led to the significant increase in these expenses. Please refer to Item 303(a)(3) of Regulation S-K and Section 501.04 of the Financial Reporting Codification.

LGND answered
The Company respectfully acknowledges the Staff’s comment and will enhance the disclosure in its future filings beginning with the 2020 Form 10-K, to address in more detail the research and development expenses for each period presented. The Company advises the Staff that it does not track research and development (R&D) expenses by program. However, the Company will discuss trends relating to changes in R&D expenses in response to the Staff’s comment.
Rest of the answer

As an example, the Company proposes to add the following additional disclosure in the 2020 Form 10-K:

“At any one time, we are working on multiple programs. As such, we generally do not track our R&D costs on a specific program basis. Our R&D costs increased year over year in 2019 due to a full year as compared to a partial year of costs associated with our 2018 acquisition of Vernalis, primarily salaries and lab costs associated with Vernalis personnel ($8.3 million) and amortization of other economic rights, primarily consisting of economic rights acquired from Palvella in December 2018 ($7.5 million) and from Novan in February 2019 ($12.0 million).”

Read in the reply
In its next report

First report after the company's reply of Jan 6, 2021: 10-K filed Feb 24, 2021 ↗, against the 10-K filed Feb 27, 2020 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Financial Statements · Note 11. Income Taxes, page 82
SEC asked (3)
We note that the deferred tax asset recorded for net operating loss carryforwards increased from $57 million at December 31, 2018 to $151 million at December 31, 2019 and the valuation allowance recorded on your deferred tax assets also increased from $4 million at December 31, 2018 to $141 million at December 31, 2019.
Rest of the question

Correspondingly, the net deferred tax assets recorded decreased from $98 million at December 31, 2018 to $43 million at December 31, 2019. We also note that the disclosures in your Form 10-K for the year ended December 31, 2019 refer to approximately $714 million of non-U.S. net operating loss carryovers and $15 million of non-U.S. capital loss carryovers for which you have recorded a full valuation allowance. It does not appear that your Form 10-K for the year ended December 31, 2018 includes disclosures regarding these non-U.S. tax attributes. In this regard, please expand your disclosures to address the following: • Please disclose what led to the significant increases in the amounts of the deferred tax asset related to net operating losses as well as the valuation allowance recorded; and • Given your disclosures elsewhere do not indicate that you had significant foreign operations in 2019, please clarify what activity in 2019 led to the $714 million of non-U.S. net operating loss carryovers and approximately $15 million of non-U.S. capital loss carryovers as of December 31, 2019, including if it was related to a specific acquisition. Refer to ASC 740-10-50-2 and 50-14.

LGND answered
The Company respectfully advises the Staff that the increase in deferred tax asset related to net operating losses as well as the valuation allowance recorded is attributable to its acquisition of Vernalis, in October of 2018. The estimated fair values of assets acquired and liabilities assumed, including deferred tax assets and liabilities, were provisional as of December 31, 2018 as the accounting for these amounts fell within the measurement period adjustments in accordance with ASC 805-10.
Rest of the answer

In 2019, the Company finalized the measurement of the acquired Vernalis deferred tax assets which mainly comprised acquired foreign net operating loss carryforwards. As part of its fair value assessment of acquired assets, the Company concluded that it was more likely than not that the benefit from the acquired foreign net operating loss carryforwards will not be realized. In recognition of this risk, the Company provided a full valuation allowance on the deferred tax assets related to these foreign net operating loss carryforwards. The Company will provide additional disclosure in its 2020 Form 10-K footnotes on the foreign net operating loss carryforwards related to its acquisition of Vernalis.

Read in the reply
In its next report

First report after the company's reply of Jan 6, 2021: 10-K filed Feb 24, 2021 ↗, against the 10-K filed Feb 27, 2020 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2021-01-13

Form 10-K for the Year Ended December 31, 2016

2017-12-15 to 2018-02-07 · 3 questions · 1 letter from the SEC, 1 from the company
Review closed 2018-02-07
Results discussion (MD&A)
Management's Discussion and Analysis of Financial Condition and Results of Operations · Results of Operations, page 32
SEC asked (1)
Please tell us the extent to which each of the increases in royalty income during the year ended December 31, 2016 and the nine months ended September 30, 2017 for Promacta/Revolade, Kyprolis and Evomela was due to volume versus price increases in sales of these products. 1. Basis of Presentation and Summary of Significant Accounting Policies
LGND answered
The Company respectfully advises the staff that its royalty partners provide the Company aggregate product sales information and therefore it is not possible to analyze to what extent the variance in royalty income is from product volume versus price increases.

1. Basis of Presentation and Summary of Significant Accounting Policies
Read in the reply
In its next report

First report after the company's reply of Jan 17, 2018: 10-K filed Mar 1, 2018 ↗, against the 10-K filed Feb 28, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Commercial License Rights, page 53
SEC asked (2)
Please provide us with a full description of your accounting for your acquired commercial license rights including your basis for recognition, measurement (initial and subsequent), and classification with reference to authoritative literature. Notes to Consolidated Financial Statements 2. Investment in Viking, page 56
LGND answered
The Company respectfully advises the staff that commercial license rights represent a portfolio of future milestone and royalty payment rights acquired from Selexis, SA (“Selexis”) in April 2013 and April 2015 for a total of $8.6 million and CorMatrix Cardiovascular, Inc. (“Cormatrix”) in May 2016 for $17.7 million. Ligand did not acquire the underlying portfolio IP or any customers of the marketed products.
Rest of the answer

Ligand does not participate in the marketing or research and development of the products and programs in these portfolios.

In May, 2016, Ligand entered into an agreement (the “Interest Purchase Agreement”) to acquire certain economic rights to payments from CorMatrix. Pursuant to the Interest Purchase Agreement, Ligand paid $17.5 million in cash and incurred $0.2 million in transaction costs to acquire the rights to receive payments, which comprised a portion of revenues from CorMatrix’s existing commercial products and the right to receive potential future payments based on future product sales from unapproved developmental pipeline products, if any. Under the Interest Purchase Agreement, Ligand was entitled to the higher of $2.75 million or 20% of CorMatrix’s annual revenues from existing commercial products with no maximum. The payments on commercial products was expected to generate approximately $2.75 million annually in the near-term and the Company estimated these payments had the potential to double over time with commercial success. The agreement was set to originally terminate with respect to each of CorMatrix’s products upon the later of (i) May 3, 2026 and (ii) 10 years from the date of the first commercial sale of such product.

The existing commercial products underlying the Interest Purchase Agreement were acquired by Aziyo Med LLC (“Aziyo”) from CorMatrix in May 2017. In connection with this, the Company entered into an amended and restated purchase agreement (the “Amended Interest Purchase Agreement”) with CorMatrix, which superseded in its entirety the Interest Purchase Agreement. Other than removing the existing commercial products sold to Aziyo in the CorMatrix sale and removing minimum payment requirements, the terms of the Amended Interest Purchase Agreement are consistent with the terms of the Interest Purchase Agreement with respect to the CorMatrix unapproved developmental pipeline products, including a royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products.

At the same time, the Company entered into a Royalty Agreement, which closed on May 31, 2017 with Aziyo, to which the Company will receive payments from the commercial products that Aziyo acquired from CorMatrix. Since the transfer of the existing commercial products sold from CorMatrix to Aziyo from the Interest Purchase Agreement to the Royalty Agreement did not result in the transfer of any consideration between the Company and either CorMatrix or Aziyo and was structured to be economically neutral to the Company, no accounting recognition was given to this transfer by the Company. Under the Interest Purchase Agreement, upon a change in control of one of the existing commercial products, the Company was due a $10 million payment and the future payments to be received related to the sold existing commercial product, would be reduced from 20% to 5%. In connection with the Royalty Agreement with Aziyo, the Company received the $10 million payment in two $5 million installments ($5 million in June 2017 and $5 million in December 2017) and the royalty was reduced from 20% to 5% as originally contemplated. In addition, pursuant to the Royalty Agreement, the future payments to be received were also reduced from 20% to 5% for the remaining commercial products in exchange for additional future consideration. That future consideration is in the form of two cumulative sales based milestones, each for $5 million when net sales proceeds received by Aziyo exceed stated amounts, and to extend the term on these payment obligations by one year. Furthermore, in each year the Company is entitled to the greater of 5% of revenues from the existing commercial products Aziyo acquired or $0 in 2017, $1.25 million in 2018, $2.2 million in 2019 and $2.75 million in 2020 and each year thereafter (i.e. through 2027). There is no maximum royalty. The agreement with Aziyo will terminate on May 31, 2027.

The Company accounts for these commercial license rights as a financial asset. The Company recognizes interest income, and amortizes the financial asset, using the effective interest method described in ASC 835-30-35-2. Pursuant to the effective interest method, the Company forecasts expected cash flows over the term of the arrangement to arrive at an annualized effective interest rate. Income is calculated by multiplying the carrying value of the commercial license right by the effective interest rate. The Company has elected to account for changes in expected cash flows as prospective adjustments to the effective yield or as an impairment, as discussed below. The estimated carrying value of the commercial license rights attributable to these agreements as of December 31, 2017 is $11.3 million. The $10.0 million royalty buy-down payments and other payments received for the year ended December 31, 2017 were accordingly allocated between income and the commercial license rights.

In performing our accounting assessment, the Company first considered whether the commercial license rights acquired were to be accounted for as a business combination. We deemed the purchase of the commercial license rights to be out of scope of the business combination guidance (ASC 805). In support of this conclusion we considered that the Company acquired the right to receive payments on existing and potential future marketed products, which could be considered an ‘output’ under the business combination accounting rules. However, the Company did not acquire any of the underlying intellectual property, employees, systems, protocols or processes to be considered an input in the business combination assessment. Further, the Company is not involved in the development, manufacturing or marketing activities of the underlying products.

Next, we considered whether the asset was an intangible asset or financial asset. To do so, we consulted the master glossary. A financial asset is defined in the ASC Master Glossary as the following:

Cash, evidence of an ownership interest in an entity, or a contract that conveys to one entity a right to do either of the following:

a.

Receive cash or another financial instrument from a second entity b.

Exchange other financial instruments on potentially favorable terms with the second entity.

A financial asset exists if and when two or more parties agree to payment terms and those payment terms are reduced to a contract. To be a financial asset, an asset must arise from a contractual agreement between two or more parties, not by an imposition of an obligation by one party on another.

An intangible asset is defined as assets, excluding financial assets that lack physical substance.

Based on the review of the contractual arrangements, we hold rights to certain future cash flows. This originally arose from a contractual agreement between Cormatrix and the Company and Selexis and the Company and as such meets the definition of a financial asset.

The Company next assessed whether or not the financial asset is a derivative. We note that the commercial license right would not meet the definition of a derivative pursuant to ASC 815 as the Company made an initial net investment that is commensurate with the amount that would be exchanged to acquire the rights to the underlying cash flows. One of the criteria of a derivative is that there must have been no, or limited, initial net investment.

The Company next assessed whether or not the financial asset should be classified as a debt security or a loan under ASC 320 and 310, respectively. ASC 320-10-20 defines a security as a share, participation, or other interest in property or in an entity of the issuer or an obligation of the issuer that has all of the following characteristics:

It is either represented by an instrument issued in bearer or registered form or, if not represented by an instrument, is registered in books maintained to record transfers by or on behalf of the issuer.

It is of a type commonly dealt in on securities exchanges or markets or, when represented by an instrument, is commonly recognized in any area in which it is issued or dealt in as a medium for investment.

c.

It either is one of a class or series or by its terms is divisible into a class or series of shares, participations, interests, or obligations.

The commercial license right was not issued in bearer form, is not in a form commonly dealt on exchanges and is not divisible, and therefore should not be considered a debt security. As a result of our analysis we concluded that the commercial license right would not be in the scope of ASC 320.

We next considered ASC 310. Under ASC 310-10-05-4 we note “Receivables may arise from credit sales, loans, or other transactions. Receivables may be in the form of loans, notes, and other types of financial instruments and may be originated by an entity or purchased from another entity.” Based on the guidance above, and because we are to receive money on fixed or determinable dates, we believe the financial asset most closely represents a loan receivable. The Company recorded the asset initially based on the amounts paid for the assets. These assets are subject to impairment which is discussed below.

Next we considered how to measure and recognize income associated to the commercial license right. The commercial license right represents the right to receive a future stream of cash flows in exchange for an upfront payment. As a receivable, the Company concluded that the commercial license right was in the scope of ASC 835-30, Imputation of Interest. ASC 835-30-15-2 states, in part:

The guidance in this Subtopic applies to receivables and payables that represent contractual rights to receive money or contractual obligations to pay money on fixed or determinable dates, whether or not there is any stated provision for interest, with certain exceptions noted below…

ASC 835-30 requires the use of the effective interest method. Therefore, the Company concluded that the excess of cash flows expected at acquisition over the amount recorded at acquisition, should be recognized as interest income on a level-yield basis over the life of the loan in accordance with the effective interest method. Because our estimates of future cash flows change over time, we made a policy election to account for changes in estimated cash flows as prospective adjustments to the effective yield. Interest income from our financial assets are recorded into revenue as we believe these activities constitute an ongoing and major component of our central operations.

As we elected a prospective approach to account for changes in estimated cash flows, we needed to select a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. While it has not occurred to date, in circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we will record impairment. Impairment will be recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate. In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we will update our yield prospectively.

The Company accounts for the Commercial license rights related to developmental pipeline products on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as the Company is not yet able to forecast future cash flows given their pre-commercial stages of development. The Company will prospectively update its yield model under the effective interest method once the underlying products are commercialized and the Company can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate.

We next considered if there are any embedded derivatives in the Commercial license rights that would require bifurcation. We analyzed the embedded features for bifurcation pursuant to ASC 815-15 and concluded there are no bifurcateable derivatives included in the arrangement.

When assessing the classification of the commercial license right in our balance sheet we have concluded to classify the financial asset as a long term asset given the imprecise nature of our cash flows and the term of the arrangement extends to at least 2027.

Notes to Consolidated Financial Statements

2. Investment in Viking, page 56

Read in the reply
In its next report

First report after the company's reply of Jan 17, 2018: 10-K filed Mar 1, 2018 ↗, against the 10-K filed Feb 28, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Commercial License Rights, page 53
SEC asked (3)
Please tell us why you have not provided the financial statements required by rule 3-09 of Regulation S-X and the disclosures required by rule 4-08(g) of Regulation S-X, and with respect to your interim financial statements included in Form 10-Q, the disclosures required by rule 10-01(b)(1) of Regulation S-X.
LGND answered
The Company respectfully acknowledges the Staff’s comments regarding the financial statements required by rule 3-09 of Regulation S-X and the disclosures required by rule 4-08(g) of Regulation S-X, and with respect to our interim financial statements included in Form 10-Q, the disclosures required by rule 10-01(b)(1) of Regulation S-X.

We acknowledge that the results of the tests for 2016 would have required separate financial statements of Viking to be included in our 2016 Form 10-K; however, we believe the results of that test are anomalous.
Rest of the answer

We submitted to the Office of Chief Accountant of the Division of Corporation Finance a request for waiver from the requirements of Rule 3-09 on January 8, 2018.

As it relates to the disclosures required by rule 4-08(g) of Regulation S-X below is the summarized financial information of Viking that would accompany the 2016 Form 10-K. We will enhance Note 2 - Investment in Viking to include the below summarized financial information in future filings of Form 10-K updated to include the required periods.

The following table presents summarized financial information of Viking:

Year ended December 31,

(in thousands)

2016

2015

2014

Condensed Statement of Operations:

Total revenue

-

Gross profit

Loss from operations

($13,847)

($11,996)

($23,468)

Net Loss

($14,732)

($23,404)

($21,884)

As of December 31,

Condensed Balance Sheet:

Current assets

$13,975

$15,202

Noncurrent assets

561

237

$14,536

$15,439

Current liabilities

$6,477

$1,977

Noncurrent liabilities

4,737

Stockholder’s equity

8,043

8,725

In addition, with respect to our interim financial statements included in Form10-Q, we will add similar summarized financial information in future filings when the significance test requirements under S-X Rule 10-01(b)(1) are met. While we do not anticipate the significance tests triggers to reach the 20% threshold as of and for the year ended December 31, 2017 or any future quarters given our anticipated increases in pre-tax income and our reduced ownership interest in Viking, we do note that for the first fiscal quarter of 2017 Ligand’s share of Viking’s pre-tax loss of $1.3 million is 21% of Ligand’s pre-tax income of $14.8 million and as a result, we will incorporate summarized financial information in the Form 10-Q for the first quarter of 2018. Ligand’s share of Viking’s pre-tax loss compared to Ligand’s pre-tax income and Ligand’s investment in Viking compared to Ligand’s total assets are below 20% for the year to date periods ending June 30, 2017 (16% and 1%, respectively) and September 30, 2017 (14% and 1%, respectively).

Read in the reply
In its next report

First report after the company's reply of Jan 17, 2018: 10-K filed Mar 1, 2018 ↗, against the 10-K filed Feb 28, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2018-02-07

Form 8-K

2016-12-19 to 2017-02-14 · 2 questions · 2 letters from the SEC, 2 from the company
Review closed 2017-02-14
Non-GAAP measuresLiquidity and cashIncome taxes
Exhibit 99.1
SEC asked
Please tell us how you intend to address in future earnings releases each of the following regarding your “adjusted financial measures” including “adjusted net income” and related per share amounts:  The lack of disclosure in explaining these measures as non-GAAP measures and why management believes each measure provides useful information to investors and the additional purposes, if any, for their use by
Rest of the question

management. Refer to Item 10(e)(1)(i)(C) and (D) of Regulation S-K.  The exclusion of an adjustment to net income for the $28.2 million gain on deconsolidation of Viking in 2015 in reconciling to adjusted net income. Refer to Question 100.03 of Non-GAAP Financial Measures Compliance & Disclosure Interpretations.  The use of adjusted net income per share. Since adjusted net income is in close proximity to your GAAP cash flows from/used in operating activities, refer to Question 102.05 of Non-GAAP Financial Measures Compliance & Disclosure Interpretations.  Not providing the tax impact to adjustments to net income to arrive at adjusted net income. Refer to Question 102.11 of Non-GAAP Financial Measures Compliance & Disclosure Interpretations.  Presenting adjusted net income for a current period and prior comparable period while only presenting GAAP net income for the current period under Third Quarter 2016 Financial Results and Year-to-Date Financial. Refer to Question 102.10 of Non-GAAP Financial Measures Compliance & Disclosure Interpretations regarding the requirement to present the most directly comparable GAAP measure with equal or greater prominence.  Exclusion from your disclosures under Revised Financial Forecast of quantitative reconciliations with respect to forward-looking non-GAAP measures. Refer to 10(e)(1)(i)(B) of Regulation S-K and the penultimate bullet of Question 102.10 of Non- GAAP Financial Measures Compliance & Disclosure Interpretations.

LGND answered
The lack of disclosure in explaining these measures as non-GAAP measures and why management believes each measure provides useful information to investors and the additional purposes, if any, for their use by management. Refer to Item 10(e)(1)(i)(C) and (D) of Regulation S-K.

Management Response:

We acknowledge the Staff's comment and reference to Item 10(e)(1)(i)(C) and (D) of Regulation S‑K.
Rest of the answer

The Company has reviewed the updated Compliance and Disclosure Interpretations issued on May 17, 2016 and will include disclosure in its future earnings releases as follows:

“The company reports non-GAAP results for diluted net income per share and net income, in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company’s financial measures under GAAP include stock-based compensation expense, amortization of debt-related costs, amortization related to acquisitions, changes in contingent liabilities, net losses of Viking Therapeutics, mark-to-market adjustment for amounts owed to licensors, fair value adjustments to Viking Therapeutics convertible note receivable and warrants, unissued shares relating to the Senior Convertible Note and adjustments for discontinued operations, and others that are listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release. However, other than with respect to total revenue, the Company only provides guidance on a non-GAAP basis and does not provide reconciliations of such forward-looking non-GAAP measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in contingent liabilities, net losses of Viking Therapeutics, mark-to-market adjustments for amounts owed to licensors and fair value adjustments to Viking Therapeutics convertible note receivable. Management has excluded the effects of these items in its non-GAAP measures to assist investors in analyzing and assessing the Company’s past and future core operating performance. Additionally, non-GAAP diluted earnings per share is a key component of the financial metrics utilized by the company’s board of directors to measure, in part, management’s performance and determine significant elements of management’s compensation.”

The exclusion of an adjustment to net income for the $28.2 million gain on deconsolidation of Viking in 2015 in reconciling to adjusted net income. Refer to Question 100.03 of Non-GAAP Financial Measures Compliance & Disclosure Interpretations.

Management Response:

We acknowledge the Staff's comment and reference to Question 100.03 of Non-GAAP Financial Measures Compliance & Disclosure Interpretations. The Company respectfully advises the Staff that it believes that its current calculation of non-GAAP net income represents a consistent and balanced approach of adjusting for the impact of certain discrete, unusual or non-cash items or for items that are outside the scope of the Company’s core operations. The Company views the $28.2 million gain on deconsolidation of Viking Therapeutics, Inc (“Viking”) in 2015 as core to its operations and therefore believes that including it in non-GAAP results is not misleading. The $28.2 million gain on deconsolidation of Viking primarily consists of the license fee, in the form of Viking common stock, we received under the Master Licensing Agreement (“MLA”) entered into between the Company and Viking in May of 2014 whereby the Company granted Viking rights to five programs in which the Company had previously made significant research and development investments. Pursuant to the MLA, as partial consideration for the grant of the rights and licenses under the MLA, upon the consummation of an initial public offering (“IPO”), Viking was required to issue to the Company shares of Viking common stock. In May 2015, Viking completed its IPO, at which time the Company received approximately 3.7 million shares of Viking common stock. While the adjustments excluded from our non-GAAP measure related to Viking typically include unrealized gains or losses on our equity and debt investment in Viking as well as our share of the losses associated with Viking as an equity method investee, the $28.2 million represents the consideration we received from a licensing arrangement, which we consider to be recurring in nature and core to our operations. Including the $28.2 million gain in the non-GAAP results is also consistent with our treatment for the considerations we received, whether in cash or in equity, under other licensing arrangements.

The use of adjusted net income per share. Since adjusted net income is in close proximity to your GAAP cash flows from/used in operating activities, refer to Question 102.05 of Non-GAAP Financial Measures Compliance & Disclosure Interpretations.

Management Response:

We acknowledge the Staff’s comment and reference to Question 102.05 of Non-GAAP Financial Measures Compliance & Disclosure Interpretations and respectfully note that the Company’s non-GAAP net income is intended to be a performance measure. The adjustments to GAAP net income are intended to assist investors in assessing the Company’s current and future operations in the way that we evaluate those operations. The adjustments may relate to cash or non-cash items depending on the nature of the item being adjusted. That is, the adjustments are not specifically intended to arrive at a cash-based measure of earnings or a liquidity measure. For example, there is a mix of non-cash items (e.g., stock-based compensation, fair value adjustments, amortization of debt issue costs and debt discounts) and items that represent cash timing differences (e.g., amortization of intangible assets and changes in contingent consideration) that are included in the Company’s non-GAAP adjustments. Rather, non-GAAP net income is presented in a manner consistent with how the Company’s management evaluates and makes decisions about business operations and is also prepared on a basis consistent with the performance metrics used to evaluate and compensate management.

Not providing the tax impact to adjustments to net income to arrive at adjusted net income. Refer to Question 102.11 of Non-GAAP Financial Measures Compliance & Disclosure Interpretations.

Management Response:

We acknowledge the Staff’s comment and have reviewed the Staff's updated Compliance and Disclosure Interpretations issued on May 17, 2016, in particular Question 102.11. In future period earnings releases we are going to revise our adjusted financial measures presentation in our earning release to remove the "non-cash tax benefit" and “non-cash tax expense” line items and to add the tax effects to the non-GAAP adjustments as a separate line item that is clearly explained in accordance with Question 102.11.

Presenting adjusted net income for a current period and prior comparable period while only presenting GAAP net income for the current period under Third Quarter 2016 Financial Results and Year-to-Date Financial. Refer to Question 102.10 of Non-GAAP Financial Measures Compliance & Disclosure Interpretations regarding the requirement to present the most directly comparable GAAP measure with equal or greater prominence.

Management Response:

We acknowledge the Staff’s comment and respectfully advise the Staff that as of the earnings release date and as disclosed in the Form 8-K dated November 3, 2016, Ligand was in the process of evaluating certain deferred tax assets (“DTA”) recorded in the third quarter of 2015 in close collaboration with its new and former auditors. The 2015 GAAP net income and earnings per share, which would be impacted by a reduction in DTA, were not available at that time. The restated figures were subsequently reported in Ligand’s Form 10-Q for the third quarter of 2016, Form 10-Q/A for the first and second quarters of 2016 and Form 10-K/A for 2015, which included the reduction in DTA. Management acknowledges the requirement to present the most comparable GAAP measure with equal or greater prominence and will revise future filings in compliance with the guidance in Question 102.10.

Exclusion from your disclosures under Revised Financial Forecast of quantitative reconciliations with respect to forward-looking non-GAAP measures. Refer to 10(e)(1)(i)(B) of Regulation S-K and the penultimate bullet of Question 102.10 of Non-GAAP Financial Measures Compliance & Disclosure Interpretations.

Management Response:

We acknowledge the Staff’s comment and respectfully advise the Staff that we will enhance our adjusted financial measure discussion to indicate that other than with respect to total revenue, the Company only provides guidance on a non-GAAP basis and does not provide reconciliations of such forward-looking non-GAAP measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. In particular, significant information is not available to calculate changes in contingent liabilities, net losses of Viking Therapeutics, mark-to-market adjustment for amounts owed to licensors and fair value adjustment to Viking Therapeutics convertible note receivable.

* * *

Read in the reply
SEC asked
We acknowledge your response to prior comment 1 of our December 19, 2016 letter. Please address the following.  Regarding your response to bullet two of our comment: o Provide us proposed disclosure to be included with your next earnings release that explains why the gain on deconsolidation of Viking is not included as a non-GAAP adjustment similar to your treatment of other adjustments related to Viking in
Rest of the question

arriving at non-GAAP adjusted net income. o Provide us an accounting analysis with reference to authoritative literature supporting your accounting for your receipt of Viking stock valued at $29.2 million as consideration in determining the $28.2 gain on deconsolidation of Viking.  Regarding your response to bullet four of our comment, tell us the effective tax rate you intend to apply to the non-GAAP adjustments in your next earnings release. Provide us, by way of example, the dollar impact to non-GAAP adjusted net income for the nine months ended September 30, 2016 and 2015 of applying those rates to those periods.

LGND answered
to bullet two of our comment:

◦

Provide us proposed disclosure to be included with your next earnings release that explains why the gain on deconsolidation of Viking is not included as a non-GAAP adjustment similar to your treatment of other adjustments related to Viking in arriving at non-GAAP adjusted net income.

Provide us an accounting analysis with reference to authoritative literature supporting your accounting for your receipt of Viking stock valued at $29.2 million as consideration in determining the $28.2 million gain on deconsolidation of Viking.

Regarding your response to
Rest of the answer

bullet four of our comment, tell us the effective tax rate you intend to apply to the non-GAAP adjustments in your next earnings release. Provide us, by way of example, the dollar impact to non-GAAP adjusted net income for the nine months ended September 30, 2016 and 2015 of applying those rates to those periods.

RESPONSE:

Regarding your response to bullet two of our comment:

Provide us proposed disclosure to be included with your next earnings release that explains why the gain on deconsolidation of Viking is not included as a non-GAAP adjustment similar to your treatment of other adjustments related to Viking in arriving at non-GAAP adjusted net income.

Management Response:

We acknowledge the Staff's comment and advise the staff that we propose adding the following disclosure to our non-GAAP adjustment footnotes:

“The $28.2 million gain on deconsolidation of Viking Therapeutics, Inc (“Viking”) in 2015 is not reflected above as a non-GAAP adjustment because the gain is primarily consideration pursuant to a licensing arrangement, which we consider to be recurring in nature and core to our operations. The $28.2 million gain comprises primarily $29.2 million in the form of Viking common stock, partially offset by certain fair value adjustments, as partial payment of the license fee we received under the Master Licensing Agreement (“MLA”) entered into between the Company and Viking in May 2014 whereby the Company granted Viking rights to five programs. Pursuant to the MLA, as partial consideration for the grant of the rights and licenses under the MLA, upon the consummation of an initial public offering, Viking was required to issue to the Company shares of Viking common stock. In May 2015, Viking completed its initial public offing, at which time the Company received approximately 3.7 million shares of Viking common stock.”

Provide us an accounting analysis with reference to authoritative literature supporting your accounting for your receipt of Viking stock valued at $29.2 million as consideration in determining the $28.2 million gain on deconsolidation of Viking.

Management Response:

We acknowledge the Staff's comment and respectfully advise the staff that we first determined whether the 3.7 million shares of Viking common stock should be viewed as revenue or consideration received from deconsolidation. In assessing that, we noted while Viking’s initial public offering (“IPO”) took place immediately before our receipt of 3.7 million shares of Viking’s common stock (“MLA shares”) as partial consideration for the grant of the rights and licenses to five programs under the MLA, we considered certain factors as discussed in ASC 810-10-40-6 to determine whether Viking’s IPO and our receipt of the MLA shares should be deemed as one single transaction in the deconsolidation of Viking.

ASC 810-10-40-6 states that a parent may cease having a controlling interest through multiple arrangements, and sometimes multiple arrangements should be accounted for as a single transaction. Under this circumstance, any of the following factors may indicate multiple arrangements that should be accounted for as a single transaction. We believe the factors are present in the two transactions we are analyzing:

They’re entered into at the same time or in contemplating each other

Viking closed its IPO on May 4, 2015, which is the same day Ligand acquired the majority of the MLA shares (i.e. 3.4 million). The remaining 0.3 million MLA shares were acquired on May 29, 2015, which is the day the underwriter exercised its overallotment, which should be considered part of the IPO transaction.

The occurrence of one arrangement is dependent on the occurrence of at least one other arrangement

In accordance with the MLA, the MLA shares, as partial license fee that Ligand is entitled to, are contingent or dependent upon Viking’s consummation of an IPO or qualified financing event as defined in the MLA.

They form a single transaction designed to achieve an overall commercial result

One arrangement considered on its own is not economically justified but they are when considering the other

In regards to the last two points above, we advise the Staff that prior to Viking’s IPO and our receipt of the MLA shares, we consolidated Viking under the variable interest entity (“VIE”) model as it was deemed that Ligand was the primary beneficiary. The five programs licensed from Ligand pursuant to the MLA comprised Viking’s sole product pipeline, and were critically important in terms of Viking completing its principal activities at the time, which focused primarily on obtaining financing. Further, the MLA included a claw-back provision giving Ligand the right to terminate the MLA if after a period of time Viking failed to obtain financing. At the IPO date (the financing event), Viking obtained full control of the license rights by having obtained financing and making a payment to Ligand in the form of MLA shares. As a result, Ligand was no longer deemed the primary beneficiary. Therefore, we viewed the IPO and the receipt of MLA shares as a single transaction that led to the deconsolidation, and the 3.7 million MLA shares received as deemed consideration received upon deconsolidation.

After determining that the 3.7 million MLA shares should be deemed consideration received upon deconsolidation, we then considered ASC 810-10-40-5 to determine how to measure the gain on deconsolidation. ASC 810-10-40-5 states:

“..a parent shall account for the deconsolidation of a subsidiary or derecognition of a group of assets specified in paragraph 810-10-40-3A: by recognizing a gain or loss in net income attributable to the parent, measured as the difference between:

a.

The aggregate of all of the following:

1. The fair value of any consideration received

Read in the reply

Also in this review: closing letter, 2017-02-14

Letters without questions

Other letters

UPLOAD and CORRESP
1 other letter: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 12 letters filed since 2016-12-19. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LGND/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.